Empini yokulwa nomdlavuza we-pancreatic, izivivinyo zomtholampilo ezintsha nezintsha sezibucayi kakhulu. Lezi zinhlolo zinikeza iziguli ukufinyelela kwangaphambi kwesikhathi ekwelashweni okuphambili okungaholela enqubekelaphambili ocwaningweni futhi kube nethemba lemiphumela engcono.
Konke ukwelashwa okutholakalayo namuhla kwacwaningwa ekuqaleni, kwathuthukiswa futhi kwagunyazwa ngokuhlolwa komtholampilo - ucwaningo locwaningo oluphenya izindlela zokwelapha ezintsha noma inhlanganisela yezindlela zokwelapha ezikhona ukuze kutholwe ukuthi ziwusizo yini kubantu abaphila nomdlavuza wamabele. Umdlavuza we-pancreatic uya ngokuya uba yinto ekhathazayo emhlabeni jikelele, uqhubekisela phambili isidingo semishanguzo yokwelapha kanye nemizamo yokuthuthukisa izidakamizwa. Izidingo ezingafezeki ezihlobene nalesi sifo ziheha izinkampani eziningi zamazwe ngamazwe ukuthi zitshale imali embonini. Lezi zinto ezihlanganiswe nokukhuphuka kwezindleko zokunakekelwa kwezempilo emhlabeni wonke kuzothuthukisa ukukhula kwemakethe. Umbiko ovela ku-Global Market Insight uthe usayizi weMakethe Yokwelapha Umdlavuza wePancreatic kulindeleke ukuthi ungenise imali eningi phakathi kuka-2021 kuya ku-2027. Lo mbiko uqhubeke wathi: “Umdlavuza we-pancreatic uthathwa njengolunye lwezinhlobo zomdlavuza ezinonya kakhulu oqala ezicutshini zama-pancreas futhi ungashesha. ukusabalala ezithweni eziseduze. Ukukhetha indlela yokuphila engenampilo njengokubhema, uphuzo oludakayo nogwayi kanye nezifo ezihlobene nendlela yokuphila njengokukhuluphala ngokweqile nesifo sikashukela ziphakathi kwezimbangela eziyinhloko zomdlavuza wamabele. I-American Cancer Society ilinganisela ukuthi abantu baseMelika abangaphezu kuka-60,000 bazotholakala benomdlavuza we-pancreatic ngo-2021. Izindlela ezifanayo ziyabonakala kwezinye izingxenye eziningi zomhlaba ezizothuthukisa ukuthambekela kwezimboni. Izinkampani ezisebenzayo ze-biotech nezekhemisi ezimakethe kuleli sonto zifaka i-Oncolytics Biotech® Inc., i-Bristol Myers Squibb, i-Seagen Inc., i-Exact Sciences Corp., i-Kura Oncology, Inc.
IGlobal Market Insight yengeze: “I-Chemotherapy, i-immunotherapy, ukwelashwa okuhlosiwe, kanye nokwelashwa ngama-hormone, phakathi kokunye, kuyizinhlobo ezahlukene zezinketho zokwelapha umdlavuza we-pancreatic. Phakathi kwalokhu, ingxenye yokwelapha okuhlosiwe ingase ibambe ingxenye efanelekile yemakethe ngo-2027. Ukwelashwa okuqondiwe kuqondise kumaprotheni athile omdlavuza, izakhi zofuzo, noma izicubu ezinomthelela ekukhuleni komdlavuza. Ukwelashwa kuvimbela ukukhula nokusabalala kwamangqamuzana omdlavuza kuyilapho kunciphisa umonakalo kwabanempilo. Ukwelashwa okuhlosiwe kuzobona ukwanda kwesidingo sokwelashwa komdlavuza we-pancreatic eminyakeni ezayo. ”
I-Oncolytics Biotech® Ihlinzeka Ngesibuyekezo Esiqondile Sokuphepha Kuqembu Lomdlavuza We-pancrea we-Multi-Indication Phase 1/2 Isivivinyo Somdlavuza Wesisu - i-Oncolytics Biotech® ) namuhla imemezele ukuphothulwa ngempumelelo komkhankaso wokuphepha weziguli ezintathu weqembu lomdlavuza we-pancreatic isigaba 1/2 socwaningo lwe-GOBLET olulandela ukuhlolwa okwenziwa yi-Data Safety Monitoring Board (DSMB) yocwaningo. I-DSMB ayiphawulanga ukukhathazeka ngokuphepha kulezi ziguli futhi yancoma ukuthi ucwaningo luqhubeke njengoba bekuhleliwe. Ukugijima kokuphepha kweqembu lomugqa wesithathu we-metastatic colorectal cancer kusaqhubeka.
Ucwaningo lwe-GOBLET luphethwe i-AIO, iqembu elihamba phambili lezemfundo elisebenzisana ne-oncology yezokwelapha elizinze eJalimane, futhi luklanyelwe ukuhlola ukuphepha nokusebenza ngempumelelo kwe-pelareorep ngokuhambisana ne-Roche's anti-PD-L1 checkpoint inhibitor atezolizumab ezigulini ezine-metastatic pancreatic, metastatic. i-colorectal, kanye nomdlavuza wezindundu osethuthukile. Ucwaningo lusaqhubeka futhi kulindeleke ukuthi lubhalise iziguli ezindaweni zokuhlolwa komtholampilo eziyi-14 kulo lonke elaseJalimane.
Iqembu lomdlavuza we-pancreatic ocwaningweni lwe-GOBLET linweba idatha yomtholampilo ebikwe ngaphambilini ekhombisa ukusebenzisana kanye nomsebenzi wokulwa nomdlavuza we-pelareorep kuhlanganiswe nokuvimbela indawo yokuhlola ezigulini ezinomdlavuza we-pancreatic ezithuthuke ngemuva kokwelashwa komugqa wokuqala (isixhumanisi esiya ku-PR, isixhumanisi sephosta). Iphinde yakhela kudatha yomtholampilo yangaphambi kwesikhathi eyabonisa ukwanda okukhulu kwamaphesenti angama-80 ekusindeni okungaqhubeki ngaphandle kokuqhubekela phambili ezigulini ezinomdlavuza we-pancreatic ezinamazinga aphansi e-CEACAM6 inkulumo ethole i-pelareorep ngokuhlanganiswa ne-chemotherapy (isixhumanisi ku-PR, isixhumanisi sephosta). Ngaphezu kokuhlola ukuphepha nokusebenza ngempumelelo kokwelashwa kwe-pelareorep-atezolizumab, i-GOBLET iphinde ifune ukubonisa amandla e-CEACAM6 kanye ne-T cell clonality njengama-biomarker abikezelayo, okungase kwandise amathuba okuphumelela ezifundweni zokubhalisa ezizayo ngokuvumela ukukhethwa kweziguli ezifanele kakhulu. .
I-Seagen Inc. isanda kumemezela idatha evela esivivinyweni somtholampilo sesigaba 1 esihlanganisa i-SEA-CD40 ne-chemotherapy kanye ne-anti-PD-1 ezigulini ezine-PDAC ye-metastatic emhlanganweni waminyaka yonke we-ASCO GI obuse-San Francisco, Januwari 20 - 22, 2022. SEA -CD40 iyinoveli, uphenyo, i-nonfucosylated monoclonal receptor-agonistic antibody eqondiswe ku-CD40, evezwa kumaseli e-antigen-presenting. Kumamodeli angaphambi komtholampilo, inhlanganisela ye-SEA-CD40 kanye nokwelashwa ngamakhemikhali kubangele umsebenzi we-antitumor othuthukiswa ngokwengeziwe ngokwelashwa kwe-anti-PD-1.
Ocwaningweni oluqhubekayo lwesigaba 1, i-SEA-CD40 yahlanganiswa ne-chemotherapy [gemcitabine ne-nab-paclitaxel (GnP)], kanye ne-anti-PD-1 (pembrolizumab), ezigulini ezingama-61 ezine-PDAC ye-metastatic engalashwanga. Kulezi, iziguli ezingu-40 zithole i-10 mcg/kg kanti iziguli ezingu-21 zithole ama-30 mcg/kg we-SEA-CD40. Iziphetho ezibalulekile zifaka isilinganiso sokuphendula esiqinisekisiwe senhloso (cORR) nge-RECIST v1.1 ngayinye ngumphenyi, i-progression-free survival (PFS) kanye nokusinda kukonke (OS) “Umsebenzi wokuqala uyakhuthaza ngokusekelwe emiphumeleni yomlando yokwelashwa ngamakhemikhali. Ukulandelela ukusinda kuyadingeka ukuze sazise izinyathelo zethu ezilandelayo ngomdlavuza we-pancreatic, "kusho uRoger Dansey, MD, Isikhulu Esiphezulu Sezokwelapha eSeagen. "Siyaqhubeka nokuqhubekisela phambili ucwaningo oluqhubekayo lwesigaba 2 se-SEA-CD40 ku-melanoma kanye nomdlavuza wamaphaphu ongewona omncane."
I-Exact Sciences Corp. muva nje imemezele idatha yokusebenza yokuhlolwa kwe-Cologuard yesizukulwane sesibili (i-multi-target stool DNA) ebonisa ukuzwela okuphelele okungu-95.2% kumdlavuza we-colorectal (CRC) kucaciswe okungu-92.4% kumasampuli angemahle aqinisekiswa yi-colonoscopy. Ukuhlaziywa kweqembu elincane kubonise ukuzwela okungama-83.3% kwe-dysplasia yezinga eliphezulu, izilonda eziyingozi kakhulu eziyingozi, kanye nama-57.2% azo zonke izilonda ezithuthukisiwe ze-precancerous. Le datha izokwethulwa ngoJanuwari 22 kwa-ASCO GI kuphosta enesihloko esithi, "Iphaneli ye-DNA yesizukulwane sesibili esihloselwe i-Stool Stool Ithola Ngokuthembekile Umdlavuza Wembala kanye Nezilonda Ezithuthukisiwe Zomdlavuza."
I-Cologuard iwukuhlolwa kokuqala nokuwukuphela kwe-FDA okugunyazwe yi-FDA, okungahlanyisi okusetshenziselwa ukuhlola abantu abasengozini emaphakathi ye-CRC. I-Exact Sciences ithuthukisa i-Cologuard yesizukulwane sesibili ukuze ithuthukise ukucaciswa nokuzwela kwe-precancer yokuhlolwa, yehlise izinga lokungamanga futhi ikhuphule izinga lokutholwa kwezilonda ezidala umdlavuza. Ucwaningo lubonisa amandla ephaneli ebandlulula kakhulu lezimpawu ze-DNA ye-methylated kanye ne-fecal hemoglobin ukuze kufezeke kokubili esimweni somhlaba wangempela. Uma kuvunyiwe, ukuhlolwa kwe-Cologuard yesizukulwane sesibili kungasiza ekukhuphuleni amazinga okuhlola kuyilapho kuthumela abantu abambalwa ekulandeleni amakholonoscopi ngokungadingekile futhi kuhlonzwe izigulane ezithuthuke kakhulu ngaphambi kokuba zithuthukele kumdlavuza, okusiza ukuvimbela isifo.
UBristol Myers Squibb usanda kumemezela ukuthi iKomidi Lemikhiqizo Yemithi Yokusetshenziswa Kwabantu (CHMP) ye-European Medicines Agency (EMA) iphakamise ukugunyazwa kwe-Breyanzi (lisocabtagene maraleucel; liso-cel), isamukeli se-chimeric antigen (CAR) T cell eqondiswe ku-CD19. Ukwelashwa kokwelashwa kweziguli ezikhulile ezine-retrapsed noma i-refractory (R/R) ehlukanisa i-B-cell lymphoma enkulu (DLBCL), i-mediastinal enkulu ye-B-cell lymphoma (PMBCL), kanye ne-follicular lymphoma grade 3B (FL3B) ngemva kwemigqa emibili noma ngaphezulu yokwelashwa kwe-systemic. Isincomo se-CHMP manje sizobuyekezwa yi-European Commission (EC), enegunya lokugunyaza imithi ye-European Union (EU).
I-Kura Oncology, Inc., inkampani ye-biopharmaceutical esesiteji somtholampilo ezibophezele ekufezeni isithembiso semithi enembile yokwelapha umdlavuza, muva nje imemezele ukuthi i-US Food and Drug Administration (FDA) iphakamise ukubanjwa kwengxenye yomtholampilo esigabeni se-KOMET-001. Ucwaningo lwe-1b lwe-KO-539 ezigulini ezine-acute myeloid leukemia (AML) ebuyele emuva noma ephikisayo. Ukubanjwa ngokwengxenye komtholampilo kwasuswa ngemva kwesivumelwano ne-FDA mayelana nesu leNkampani lokunciphisa le-differentiation syndrome, isenzakalo esibi esaziwayo esihlobene nama-ejenti ahlukanisayo ekwelapheni i-AML.
